论文部分内容阅读
本研究采用抗ＣＤ３单克隆抗体（ＣＤ３ＭｃＡｂ）辅以少量的基因重组人白细胞介素２（γＩＬ—２）和植物血凝素（ＰＨＡ）诱导外周血淋巴细胞，成功地研制出具有抗瘤活性的ＣＤ３ＭｃＡｂ激活的杀伤细胞（ＣＤ３ＡＫ细胞）。结果表明：微量的ＣＤ３ＭｃＡｂ辅以少量的γＩＬ—２和ＰＨＡ就能诱导并大量扩增ＣＤ３ＡＫ细胞。３０ｎｇ／ｍｌ的ＣＤ３ＭｃＡｂ就能一次性激活ＣＤ３ＡＫ细胞，当ＣＤ３ＭｃＡｂ浓度提高到３００ｎｇ／ｍｌ时，ＣＤ３ＡＫ细胞的扩增能力明显高于ＬＡＫ细胞；ＣＤ３ＡＫ细胞是以ＣＤ３＋、ＣＤ８＋和ＣＤ４＋细胞为主的异质性细胞群，ＣＤ３＋和ＣＤ８＋细胞百分率随培养时间延长而增加，培养第４天至第１６天的ＣＤ３ＡＫ细胞均有很强的杀瘤活性，而最佳时期在第７天至第１０天；其体外杀瘤活性明显高于ＬＡＫ细胞（Ｐ＜０．０５）。本实验研究表明：ＣＤ３ＡＫ细胞是继ＬＡＫ、ＴＩＬ后又一更为有效的杀瘤细胞。
In this study, anti-CD3 monoclonal antibody (CD3McAb) was supplemented with a small amount of recombinant human interleukin 2 (γIL-2) and phytohemagglutinin (PHA) to induce peripheral blood lymphocytes, and successfully developed anti-tumor activity. CD3 McAb-activated killer cells (CD3AK cells). The results showed that a small amount of CD3McAb supplemented with a small amount of γIL-2 and PHA can induce and massively expand CD3AK cells. The CD3AKAb could be activated once by 30ng/ml CD3McAb. When the CD3McAb concentration was increased to 300ng/ml, the CD3AK cell amplification ability was significantly higher than that of LAK cells; CD3AK cells were mainly heterogenous with CD3+, CD8+, and CD4+ cells. The percentage of cell populations, CD3+ and CD8+ cells increased with the prolongation of culture time. CD3AK cells from the 4th day to the 16th day had a strong tumoricidal activity, and the optimal period was from the 7th day to the 10th day. The tumoricidal activity in vitro was significantly higher than LAK cells (P<0.05). This experimental study shows that CD3AK cells are another more effective killer tumor cells after LAK and TIL.